# Pizarra — PT-pseudo_d49b896a09e6 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d49b896a09e6
Task: 1

Encounter: Urology - outpatient on 31 Jan 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 6.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.2 ng/mL²
  - PSA velocity: 1.78 ng/mL/yr
  - Prior PSA: 4.4 ng/mL
  - Prostate volume: 36.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7934635 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30)
  - Current medication: rosuvastatin, aspirin 80 mg, atorvastatin
  - Allergies: NKA
  - Additional notes: PSA 6.7 ng/mL. PI-RADS 4. PSAD 0.20. Prostate volume 36 mL. csPCa 0.79.

Vitals: weight 93 kg, height 178 cm, BMI 29.4, BP 146/77 mmHg, HR 77 bpm. Smoking: Current smoker (17 pack-yr).

Chief complaint: An upward PSA trend alongside a previously positive biopsy necessitates urological review.

History: A widowed retired warehouse worker currently residing with his partner presents for surveillance after a positive biopsy yielded a Gleason 6 diagnosis. His medical background includes coronary artery disease, hypercholesterolaemia, and obesity (BMI >30). Daily medication consists of rosuvastatin, atorvastatin, and aspirin 80 mg. He maintains a 17 pack-year smoking history and consumes approximately 19 units of alcohol each week. Despite a consistent running routine covering five kilometres three times weekly, he reports moderate lower urinary tract symptoms scoring 13 on the IPSS scale, absent of significant nocturia or urgency. Cardiology reviewed him in November, confirming stable angina without recent procedures. An unrelated cataract evaluation occurred last month, and he mentions occasional mild fatigue he attributes to seasonal shifts rather than systemic disease. Distance to the hospital exceeds ninety minutes, leading him to prefer telephone consultations when clinically suitable.

Physical examination: DRE — texture: smooth and symmetric; mobility: unremarkable; asymmetry: none. The digital rectal examination confirms a normal prostate without palpable irregularities. General inspection shows a well-nourished individual with a blood pressure reading of 146/77 mmHg and a regular pulse of 77 beats per minute. Palpation of the abdomen reveals a soft, non-tender abdomen free of masses or organomegaly.

Patient info: retired warehouse worker; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 19 units / week; exercise Running 3x/week, 5 km; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Ophthalmology — cataract review.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.56 +/- 0.20   (95% CI 0.16-0.91)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.13  (few labelled cases resemble this one)
  - 7.0 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=6.7, age=67.0, psad=0.2, dre_ord=0.0, vol=36.0, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel variables (PI-RADS=4.0, PSA=6.7, PSA density=0.2, DRE=Normal, Prostate volume=36.0 mL, Prior biopsy=Positive, csPCa probability=0.7934635) and could not weigh the clinical context, such as the specific Gleason grade from the prior positive biopsy, the stability of the PI-RADS 4 lesion over time, or the specific findings from the retrieved MRI report.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy with a 56% probability, which is a 'discuss' tier result. This suggests the panel is genuinely inconclusive. This could be wrong because the prior failed to account for the guideline criterion that the decision hinges on the retrieved documents (MRI prose, PSA trajectory, etc.), which the prior explicitly stated it had not seen. Furthermore, a high csPCa probability (0.79) combined with a prior positive biopsy might make the question "does he have cancer" less relevant than assessing lesion stability, as noted by the protocol expert.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes
laboratory panel

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_d49b896a09e6", "radiology_report": "UMCG Groningen | 28 January 2025 | mpMRI prostate\n\nIndication: Reassessment after a previously positive biopsy in a 67-year-old gentleman with a PSA of 6.7 ng/mL and a prior PI-RADS 4 designation.\n\nFINDINGS:\nThe prostate gland occupies 36.0 mL of volume. Within the left peripheral zone at the mid-gland level, a discrete abnormality measures roughly 12 x 8 mm. T2-weighted sequences show this focus as sharply demarcated hypointensity. Diffusion-weighted imaging reveals pronounced restriction, mirrored by corresponding low signal on the ADC map. Dynamic contrast enhancement demonstrates prompt, localized uptake compared to adjacent tissue. There is no seminal vesicle invasion or extraprostatic extension.\n\nIMPRESSION:\nPI-RADS 4 lesion in the left peripheral zone, mid-gland, measuring approximately 12 x 8 mm. Prostate volume 36.0 mL, yielding a PSA density of 0.2 ng/mL/mL. csPCa predicted probability 0.7934635."}
get_psa_trend
{"case_id": "PT-pseudo_d49b896a09e6", "psa_trend": [{"date": "Oct 2023", "val": 3.0}, {"date": "Mar 2024", "val": 3.9}, {"date": "Aug 2024", "val": 5.1}, {"date": "Jan 2025", "val": 6.7}]}
get_previous_notes
{"case_id": "PT-pseudo_d49b896a09e6", "previous_notes": [{"date": "03 Oct 2024", "author": "Dr. P. van Dijk (GP)", "text": "PSA climbed to 4.4 ng/mL during routine screening. The gentleman experiences moderate lower urinary tract symptoms, registering an IPSS score of 13. Given the upward trajectory and his history of a positive biopsy, he was referred to urology for further assessment."}, {"date": "10 Aug 2023", "author": "Dr. P. van Dijk (GP)", "text": "An initial PSA reading of 3.1 ng/mL was documented. Digital rectal examination showed no abnormalities. The clinical team arranged a repeat PSA measurement in six months to track progression while focusing on cardiovascular risk optimization."}]}
get_lab_results
{"case_id": "PT-pseudo_d49b896a09e6", "laboratory_results": [{"name": "PSA", "val": "6.7 ng/mL", "date": "24 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.01 ng/mL", "date": "24 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "15%", "date": "24 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.4 g/dL", "date": "24 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.0 x10^9/L", "date": "24 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "264 x10^9/L", "date": "24 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "81 umol/L", "date": "24 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "24 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "13.4 nmol/L", "date": "24 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "73 U/L", "date": "24 Dec 2024", "flag": ""}, {"name": "LDH", "val": "157 U/L", "date": "24 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The specific ISUP grade group or Gleason score from the prior positive biopsy was not documented in the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity of 1.78 ng/mL/yr, showing a clear upward trend from 3.0 ng/mL (Oct 2023) to 6.7 ng/mL (Jan 2025).
- The mpMRI shows a PI-RADS 4 lesion (12 x 8 mm) in the left peripheral zone, which is a new finding in the context of the prior positive biopsy.

AGAINST sampling this patient now:
- DRE findings are Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
- The mpMRI report explicitly states "There is no seminal vesicle invasion or extraprostatic extension."

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the rising PSA trend and the presence of a new, high-risk lesion on the MRI. This leans towards recommending a re-biopsy or further targeted sampling to characterize the lesion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the evidence strongly suggests further investigation due to the PSA velocity of 1.78 ng/mL/yr and the presence of a new PI-RADS 4 lesion on the mpMRI. Since the prior ISUP grade was not documented in the retrieved reports, sampling is necessary to characterize the lesion and determine the appropriate management pathway. The statistical prior suggested biopsy, and the retrieved evidence supports proceeding with further sampling.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=important
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
